GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China NT Pharma Group Co Ltd (HKSE:01011) » Definitions » Beta

China NT Pharma Group Co (HKSE:01011) Beta : 0.11 (As of Apr. 05, 2025)


View and export this data going back to 2011. Start your Free Trial

What is China NT Pharma Group Co Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2025-04-05), China NT Pharma Group Co's Beta is 0.11.


China NT Pharma Group Co Beta Historical Data

The historical data trend for China NT Pharma Group Co's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China NT Pharma Group Co Beta Chart

China NT Pharma Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.27 0.37 0.26 0.27

China NT Pharma Group Co Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.64 0.26 0.28 0.27 0.53

Competitive Comparison of China NT Pharma Group Co's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, China NT Pharma Group Co's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China NT Pharma Group Co's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China NT Pharma Group Co's Beta distribution charts can be found below:

* The bar in red indicates where China NT Pharma Group Co's Beta falls into.


;
;

China NT Pharma Group Co Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


China NT Pharma Group Co  (HKSE:01011) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


China NT Pharma Group Co Beta Related Terms

Thank you for viewing the detailed overview of China NT Pharma Group Co's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


China NT Pharma Group Co Business Description

Traded in Other Exchanges
N/A
Address
198 Wellington Street, 28th Floor, The Wellington, Sheung Wan, Hong Kong, HKG
China NT Pharma Group Co Ltd is a technology-based pharmaceutical company. It is engaged in research and development, production, and sale of private-label drugs, as well as the provision of pharmaceutical marketing and promotion services in China. It focused on the research, development, production, and sales of orthopedic, psychiatric, and oncology drugs. The company operates in a single segment of Proprietary product production and sales. The company earns the majority of its revenue from the domestic market. The Group's revenue from an external customer was derived solely from its operations in the PRC.
Executives
Ieong Chong Mang
Golden Base Investment Limited
Wang Minzhi 2101 Beneficial owner
Shum Ning
Chin Yu
Ng Tit
Ieong Iat 2101 Beneficial owner

China NT Pharma Group Co Headlines

No Headlines